Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03763565
Other study ID # HPV 021
Secondary ID 2561.1/13
Status Completed
Phase
First received
Last updated
Start date November 1, 2018
Est. completion date July 1, 2019

Study information

Verified date June 2023
Source Mahidol University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

- Background: The majority of the burden of HPV-related cervical cancer is in developing countries while most of the effectiveness reports of HPV vaccination are currently coming from developed countries. Also, currently many adult women are left without either HPV vaccination or cervical cancer screening. Effectiveness data of currently available HPV vaccines among adult women in developing countries are needed for women and healthcare workers and policy makers to best protect women from cervical cancer. - Primary Study Objective: - To determine the effectiveness bivalent and quadrivalent HPV vaccines in reduction of cervical dysplasia (Low-grade Squamous Intraepithelial Lesion or worse; LSIL+) attributable to HPV types 16 or 18 after at least 5 years of vaccination among Thai women vaccinated at their ages 20-45 years with at least one dose of the HPV vaccine - Secondary Study Objectives: - To measure the effectiveness of currently available bivalent and quadrivalent HPV vaccines in reducing the prevalence of HPV 16 or 18 - To measure the effectiveness of HPV vaccines in reducing any abnormal Pap smear result (ASC-US+) - To compare the effectiveness of HPV vaccines according to the number of doses immunized - To find out risk factor(s) for HPV 16 or 18-related cervical dysplasia in this cohort - To assess the prevalence of other high-risk HPV types in vaccinated and non-vaccinated group - To determine direct and/or indirect cost of HPV vaccination - The hypothesis to be tested: At least one dose of vaccination with bi- or quadri-valent HPV vaccine will reduce the prevalence of LSIL+ attributable to HPV 16/18 by 80% after at least 5 years of vaccination. - Materials and Methods: This study will be a retrospective matched cohort study. Data is to be collected either by from samples for Pap and HPV test and/or HPV 16/18 genotyping of the recruited participants, or from existing medical records. HPV vaccinated women at their ages 20-45 years (vaccinated group) and women received Pap smear at their ages 20-45 years without vaccination (control group) will be included in the study. Pap smear and HPV test and/or HPV 16/18 typing result of 2 groups will be compared after ≥ 5 years of vaccination or baseline Pap smear. Those who don't have Pap smear results ≥ 5 years after vaccination or ≥ 5 years after the baseline Pap smear will be offered for a Pap smear and HPV 16/18 typing


Recruitment information / eligibility

Status Completed
Enrollment 993
Est. completion date July 1, 2019
Est. primary completion date July 1, 2019
Accepts healthy volunteers
Gender Female
Age group 25 Years to 53 Years
Eligibility Inclusion Criteria (vaccinated group) - Thai women aged 20-45 years at the time of HPV vaccination - Received at least 1 dose of bivalent or quadrivalent HPV vaccine at least 5 years ago - Willing to provide written informed consent and receive Pap smear & HPV genotyping (only for those who need specimen collection for cervical cytology and HPV genotyping result) (control group) - Thai women without history of HPV vaccination - Received Pap smear result at their ages 20-45 years at least 5 years ago - Willing to provide written informed consent and receive Pap smear & HPV genotyping (only for those who need specimen collection for cervical cytology and HPV genotyping result) Exclusion Criteria: - Known pregnancy - History of hysterectomy or excisional treatment of the cervix - Known increased risk of bleeding - Not willing to provide written informed consent

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Bivalent or Quadrivalent HPV vaccines
Vaccination with at least one dose of Bivalent or Quadrivalent HPV vaccines at least 5 years ago at the ages of 20-45 years
Other:
Control group
Thai women who did not receive HPV vaccination, either by bivalent or quadrivalent HPV vaccine but have received Pap smear at their ages 20-45 years at least 5 years ago from the current enrollment time

Locations

Country Name City State
Thailand Bumrungrad International Hospital Bangkok
Thailand King Chulalongkorn Memorial Hospital Bangkok
Thailand National Cancer Institute, Thailand Bangkok
Thailand Siriraj Hospital, Mahidol University Bangkok
Thailand Vaccine Trial Centre, Faculty of Tropical Medicine, Mahidol University, Bangkok

Sponsors (6)

Lead Sponsor Collaborator
Mahidol University Bumrungrad International Hospital, Chulalongkorn University, National Cancer Institute, Thailand, National Vaccine Institute, Thailand, Siriraj Hospital

Country where clinical trial is conducted

Thailand, 

Outcome

Type Measure Description Time frame Safety issue
Primary Occurrence of Low-grade squamous intraepithelial lesion or worse (LSIL+) associated with HPV 16 or 18 LSIL or worse, including Atypical Glandular Cells, High-grade squamous intraepithelial lesion, Cervical intraepithelial neoplasia (CIN) grade 1-3, and cervical cancer which are associated with either HPV 16 or 18 Sample collection in the project is single 1 day time for participants who received vaccination at least 5 years ago.
Secondary Cost-effectiveness of bivalent and quadrivalent HPV vaccination Direct and and indirect cost survey interview associated with HPV vaccination and its cost-effectiveness Interview for direct and indirect cost survey will be single 1 day time for a participant.
See also
  Status Clinical Trial Phase
Completed NCT01505920 - Lidocaine Spray Compared With Submucosal Injection During LEEP: a Randomized Controlled Trial Phase 3
Completed NCT01014026 - Self-sampling and Human Papillomavirus (HPV)-Testing for Unscreened Women in Cervical Cancer Prevention Phase 3
Completed NCT00377845 - Cervix Cytological Screening - Comparison of Tampon Self-Test and the Routine Smear. Phase 0
Completed NCT02910388 - LLETZ Under Direct Colposcopic Vision N/A
Completed NCT00596258 - A Two-Stage Phase 2 Study Of A-007 Topical Gel in High-Grade Squamous Intraepithelial Lesions (HSIL) Phase 2
Completed NCT04415840 - Lugol's Solution in Addition to Acetic Acid During Colposcopy
Recruiting NCT04783805 - Conservative Management of HSIL in Patients With Future Pregnancy Aspiration
Completed NCT04326049 - LLETZ With Videocolposcopy Versus LLETZ With Binocular Colposcopy N/A
Completed NCT02515162 - Fischer Cone Biopsy Excisor Versus Loop Excision Procedure for Conization N/A
Completed NCT02486471 - Hemostatic Procedure After Biopsy of the Cervix N/A
Completed NCT01405768 - Buffered Lidocaine for Loop Electrosurgical Excision Procedures (LEEPs) Phase 2
Completed NCT00264732 - A Study of Amolimogene (ZYC101a) in Patients With High Grade Cervical Intraepithelial Lesions of the Uterine Cervix Phase 2/Phase 3
Completed NCT03296566 - The SAFE Study: Satisfaction and Adherence to Follow-Up With Colposcopy Exams N/A
Completed NCT02346227 - Impact of AV2 Antiviral Drug on the Treatment of HPV-associated Lesions of the Uterine Cervix Phase 3
Completed NCT02330471 - Forced Versus Spray Coagulation in Women Undergoing LLETZ-conization for Cervical Dysplasia: a Randomized Trial Phase 3
Completed NCT01035580 - Trial on Safety and Pharmacokinetics of Intravaginal Curcumin Phase 1
Completed NCT01639820 - Comparison of Pelvic Lymphadenectomy Versus Isolated Sentinel Lymph Node Biopsy Procedure for Early Stages of Cervical Cancers : a Multicenter Study With Evaluation of Medico-economic Impacts N/A
Completed NCT00285207 - Safety and Efficacy of A-007 Topical Gel in the Treatment of High-Grade Squamous Intraepithelial Lesions (HSIL) of the Cervix Phase 2
Recruiting NCT05225493 - HIV Indicator Diseases in Hospital and Primary Care
Completed NCT01034358 - Immune Response to the Human Papillomavirus Vaccine in Young Women With Inflammatory Bowel Disease Phase 4